SNWV
SANUWAVE Health, Inc. NASDAQ$15.64
Mkt Cap $134.4M
52w Low $15.36
0.9% of range
52w High $46.59
50d MA $20.13
200d MA $29.74
P/E (TTM)
11.4x
EV/EBITDA
42.8x
P/B
83.2x
Debt/Equity
14.2x
ROE
729.6%
P/FCF
132.1x
RSI (14)
—
ATR (14)
—
Beta
1.51
50d MA
$20.13
200d MA
$29.74
Avg Volume
71.6K
About
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | 0.17 | 0.03 | -82.4% | 18.85 | -11.1% | -1.3% | -7.7% | -8.3% | -10.6% | -10.3% | -2.1% | — |
| Nov 7, 2025 | AMC | 0.32 | 0.46 | +43.8% | 31.08 | +0.4% | +10.2% | +13.7% | +7.3% | +8.0% | +6.1% | -3.9% | — |
| Aug 8, 2025 | AMC | -0.09 | 0.01 | +111.1% | 39.76 | +5.6% | +7.5% | +4.9% | +0.3% | -5.0% | -2.9% | -9.7% | — |
| May 9, 2025 | AMC | — | -0.66 | — | 30.10 | +1.9% | +1.5% | +10.5% | +13.9% | +4.0% | +7.3% | +0.2% | — |
| Mar 20, 2025 | AMC | — | -1.21 | — | 32.00 | +4.3% | +17.5% | +21.0% | +18.8% | +17.2% | +16.5% | -12.5% | — |
| Nov 7, 2024 | AMC | — | -6.49 | — | 19.40 | +3.9% | +14.4% | +15.5% | +15.5% | +17.7% | +18.6% | +2.3% | — |
| Aug 12, 2024 | AMC | — | 3.70 | — | 5.77 | +10.4% | +4.0% | -2.6% | +4.0% | -1.2% | +4.0% | +0.7% | — |
| May 9, 2024 | AMC | — | -1.46 | — | 8.25 | +2.3% | +4.1% | -5.7% | -9.6% | -9.1% | -5.0% | -18.2% | — |
| Mar 21, 2024 | AMC | — | 11.11 | — | 7.50 | -7.5% | -1.2% | +4.9% | +2.5% | +7.7% | +7.7% | +7.5% | — |
| Nov 9, 2023 | AMC | — | -3.70 | — | 5.57 | +0.9% | -5.7% | -9.9% | -1.1% | -7.7% | -9.2% | -19.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Roth Capital | Maintains | Buy → Buy | — | $18.61 | $18.72 | +0.6% | -6.6% | -7.1% | -9.5% | -9.2% | -8.1% |
| Aug 22 | Roth Capital | Maintains | Buy → Buy | — | $41.26 | $41.93 | +1.6% | +9.1% | +3.4% | +1.8% | +7.5% | +2.9% |
| Sep 15 | Lake Street | Maintains | Buy → Buy | — | $83.44 | $80.62 | -3.4% | -1.1% | -3.5% | -1.0% | -0.2% | -0.6% |
Recent Filings
8-K
Unknown — 8-K Filing
Sanuwave met Q1 guidance with modest 3-4% revenue growth, suggesting stable market demand for its wound care devices, though slow growth may concern investors seeking acceleration.
Apr 16
8-K
Unknown — 8-K Filing
SNWV's 29.7% year-over-year Q4 revenue growth to a record $13.4 million demonstrates strong demand momentum, suggesting the company is successfully executing its business strategy and may sustain profitability improvements.
Mar 26
8-K
Unknown — 8-K Filing
Snowview's planned financial restatement signals potential accounting errors in 2024 results, raising red flags about internal controls and creating uncertainty around actual financial performance that investors relied upon.
Mar 13
Data updated apr 27, 2026 2:16am
· Source: massive.com